相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Novel risk factors for glucarpidase use in pediatric acute lymphoblastic leukemia: Hispanic ethnicity, age, and the ABCC4 gene
Mark C. Zobeck et al.
PEDIATRIC BLOOD & CANCER (2021)
Risk prediction for delayed clearance of high-dose methotrexate in pediatric hematological malignancies by machine learning
Min Zhan et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2021)
Population pharmacokinetics of methotrexate in Mexican pediatric patients with acute lymphoblastic leukemia
Susanna E. Medellin-Garibay et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2020)
Financial toxicity of childhood cancer and changes to parents' employment after treatment completion
Lauren Kelada et al.
PEDIATRIC BLOOD & CANCER (2020)
MTXPK.org: A Clinical Decision Support Tool Evaluating High-Dose Methotrexate Pharmacokinetics to Inform Post-Infusion Care and Use of Glucarpidase
Zachary L. Taylor et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Risk factors for high-dose methotrexate associated acute kidney injury in patients with hematological malignancies
Irina Amitai et al.
HEMATOLOGICAL ONCOLOGY (2020)
Hispanic ethnicity is associated with prolonged clearance of high dose methotrexate and severe nephrotoxicity in children and adolescents with acute lymphoblastic leukemia
Dolores Mullikin et al.
LEUKEMIA & LYMPHOMA (2020)
The impact of childhood cancer on parents' socio-economic situation-A systematic review
Katharina Roser et al.
PSYCHO-ONCOLOGY (2019)
Impact of Ethnicity on Toxicities Associated with Dose Escalating Methotrexate in Pediatric Patients with Acute Lymphoblastic Leukemia
Ashley Siryk et al.
BLOOD (2019)
A prospective study of a simple algorithm to individually dose high-dose methotrexate for children with leukemia at risk for methotrexate toxicities
Jennifer H. Foster et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
Identification of Risk Factors in High-Dose Methotrexate-Induced Acute Kidney Injury in Childhood Acute Lymphoblastic Leukemia
Dao-Hai Cheng et al.
CHEMOTHERAPY (2018)
Disparities in Neurotoxicity Risk and Outcomes among Pediatric Acute Lymphoblastic Leukemia Patients
Olga A. Taylor et al.
CLINICAL CANCER RESEARCH (2018)
Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia
Thommy Svahn et al.
PEDIATRIC BLOOD & CANCER (2017)
Practical Bayesian model evaluation using leave-one-out cross-validation and WAIC
Aki Vehtari et al.
STATISTICS AND COMPUTING (2017)
brms: An R Package for Bayesian Multilevel Models Using Stan
Paul-Christian Buerkner
JOURNAL OF STATISTICAL SOFTWARE (2017)
Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia
Shu-Guang Liu et al.
ONCOTARGET (2017)
Genetic variation underlying renal uric acid excretion in Hispanic children: the Viva La Familia Study
Geetha Chittoor et al.
BMC MEDICAL GENETICS (2017)
Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity
Tracy Wiczer et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2016)
Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia
Samantha N. Reiss et al.
ANNALS OF HEMATOLOGY (2016)
Preventing and Managing Toxicities of High-Dose Methotrexate
Scott C. Howard et al.
ONCOLOGIST (2016)
Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia
M. A. H. den Hoed et al.
PHARMACOGENOMICS JOURNAL (2015)
Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia
Katalin Csordas et al.
ANTI-CANCER DRUGS (2013)
Genome-wide study of methotrexate clearance replicates SLCO1B1
Laura B. Ramsey et al.
BLOOD (2013)
Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients
Anthony M. Christensen et al.
CANCER (2012)
Pharmacogenomics Knowledge for Personalized Medicine
M. Whirl-Carrillo et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition
Laura B. Ramsey et al.
GENOME RESEARCH (2012)
Plasma Methotrexate, Red Blood Cell Methotrexate, and Red Blood Cell Folate Values and Outcome in Children With Precursor B-acute Lymphoblastic Leukemia A Report From the Children's Oncology Group
Wanda L. Salzer et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2012)
Polymorphisms in the methotrexate transport pathway
Elixabet Lopez-Lopez et al.
Pharmacogenetics and Genomics (2012)
PharmGKB summary: methotrexate pathway
Torben S. Mikkelsen et al.
PHARMACOGENETICS AND GENOMICS (2011)
The association of reduced folate carrier 80G>A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number
Jannie Gregers et al.
BLOOD (2010)
SLC19A1 pharmacogenomics summary
Sook Wah Yee et al.
PHARMACOGENETICS AND GENOMICS (2010)
A genomewide admixture mapping panel for hispanic/latino populations
Xianyun Mao et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2007)
Ancestry and phannacogenetics of antileukernic drug toxicity
Shinji Kishi et al.
BLOOD (2007)
Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia
Nobuko Hijiya et al.
BLOOD (2006)
Understanding and managing methotrexate nephrotoxicity
Brigitte C. Widemann et al.
ONCOLOGIST (2006)
Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia
Dolores Aumente et al.
CLINICAL PHARMACOKINETICS (2006)
Survival variability by race and ethnicity in childhood acute lymphoblastic leukemia
NS Kadan-Lottick et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
分享论文
